Invesco announced on Feb. 28 that Andrey Belov, an analyst on Invesco International Small-Mid Company OSMAX, has been promoted to comanager. Belov has 26 years of investment experience. He joined Invesco in 2020 after previous stints as an analyst on a fund with a similar focus at Lord Abbett and a longer tenure as an analyst and comanager at Cramer Rosenthal McGlynn. The lead manager of the strategy remains David Nadel, and no changes of approach are planned. The strategy’s People and Process ratings remain unchanged following Belov's promotion.
Invesco International Small-Mid Com Y OSMYX
- NAV / 1-Day Return 40.42 / +1.35 %
- Total Assets 4.7 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.110%
- Distribution Fee Level Above Average
- Share Class Type Institutional
- Category Foreign Small/Mid Growth
- Investment Style Mid Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 1.08%
- Turnover 26%
USD | NAV as of Apr 22, 2024 | 1-Day Return as of Apr 22, 2024, 10:14 PM GMT+0
Morningstar’s Analysis OSMYX
Will OSMYX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 17.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Carl Zeiss Meditec AG | 2.47 | 123.1 Mil | Healthcare |
Croda International PLC | 2.33 | 116.1 Mil | Basic Materials |
OBIC Co Ltd | 2.07 | 103.4 Mil | Technology |
NICE Ltd ADR | 1.79 | 89.0 Mil | Technology |
Diasorin SpA | 1.68 | 84.0 Mil | Healthcare |
Partners Group Holding AG | 1.65 | 82.1 Mil | Financial Services |
Vz Hldg Ag | 1.49 | 74.5 Mil | — |
Bruker Corp | 1.34 | 66.7 Mil | Healthcare |
Icon PLC | 1.33 | 66.5 Mil | Healthcare |
Sartorius AG Participating Preferred | 1.30 | 64.7 Mil | Healthcare |